Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ardelyx, Inc.

< Previous 1 2 Next >
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.